New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists
- 23 June 2005
- journal article
- review article
- Published by Elsevier in Life Sciences
- Vol. 77 (26) , 3259-3267
- https://doi.org/10.1016/j.lfs.2005.04.029
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Translating A 2A antagonist KW6002 from animal models to parkinsonian patientsNeurology, 2003
- A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s diseaseExperimental Neurology, 2003
- Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic‐intermittent L‐dopa and A2A receptor blockade plus L‐Dopa in dopamine‐denervated ratsSynapse, 2002
- Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's DiseaseJournal of Neuroscience, 2001
- Prospective study of caffeine consumption and risk of Parkinson's disease in men and womenAnnals of Neurology, 2001
- The role of the D 2 dopamine receptor (D 2 R) in A 2A adenosine receptor (A 2A R)-mediated behavioral and cellular responses as revealed by A 2A and D 2 receptor knockout miceProceedings of the National Academy of Sciences, 2001
- Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2A Receptor AntagonistJournal of Neuroscience, 2000
- Functional GluR6 Kainate Receptors in the Striatum: Indirect Downregulation of Synaptic TransmissionJournal of Neuroscience, 2000
- Adenosine A2a receptors in the nucleus accumbens mediate locomotor depressionBrain Research Bulletin, 1993
- Both A1 and A2a Purine Receptors Regulate Striatal Acetylcholine ReleaseJournal of Neurochemistry, 1990